Tomonori Nakazato

14PUBLICATIONS
4CO-AUTHORS
Gene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Oct 25, 2024
The Real-World Outcomes of Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab, Pomalidomide, and Dexamethasone.

Hitomi Nakayama, Yoshinobu Aisa, Chisako Ito

|Mar 21, 2024
Effective treatment of pleural effusion in chronic lymphocytic leukemia with acalabrutinib: a case report.

Shuhei Kurosawa, Takako Yokota, Yusuke Takada

|Nov 27, 2023
Evaluation of the cachexia index using a bioelectrical impedance analysis in elderly patients with non-Hodgkin's lymphoma: A single-center prospective study.

So Okubo, Kohei Shinmura, Saori Kadota

|Nov 17, 2022
Polatuzumab vedotin plus bendamustine and rituximab (Pola-BR) was effective for neurolymphomatosis in a patient with refractory diffuse large B-cell lymphoma.

Kohei Shinmura, So Okubo, Saori Kadota

|Apr 29, 2022
Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors.

Yuriko Nishiyama-Fujita, Tomonori Nakazato, Noriyoshi Iriyama

|Aug 01, 2021
Phase II clinical trial of personalized VCD-VTD sequential therapy using the Vulnerable Elders Survey-13 (VES-13) for transplant-ineligible patients with newly diagnosed multiple myeloma.

Tomonori Nakazato, Masao Hagihara, Naohi Sahara

Pageof 3

Frequent Collaborators

4 joint publications

Yuriko Nishiyama-Fujita

1 joint publications

Takahiro Kamiya

1 joint publications

Norio Komatsu

1 joint publications

Shuhei Kurosawa